InflaRx (IFRX) Assets Average (2017 - 2026)
InflaRx (IFRX) posted Assets Average of $60.8 million for Q1 2026, down 13.48% sequentially from $70.2 million in Q4 2025, and down 29.66% YoY from $86.4 million in Q1 2025.
InflaRx (IFRX) Assets Average (2017 - 2026) Analysis & Trends
InflaRx has reported Assets Average for 10 years, with the latest figure at $60.8 million in Q1 2026.
- Quarterly Assets Average fell 29.66% year-over-year to $60.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.8 million (down 29.66% YoY) and the FY2025 annual result came in at $72.3 million, down 31.86% from the prior year.
- Assets Average declined to $60.8 million in Q1 2026 per IFRX's latest filing, from $70.2 million in the prior quarter.
- Over five years, Assets Average peaked at $142.9 million in Q3 2023 and troughed at $60.8 million in Q1 2026.
- A 5-year average of $104.5 million and a median of $108.3 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average climbed 24.84% in 2023, then sank 37.57% in 2024.
- Over 5 years, Assets Average stood at $108.3 million in 2022, then increased by 24.84% to $135.1 million in 2023, then slumped by 37.57% to $84.4 million in 2024, then fell by 16.77% to $70.2 million in 2025, then retreated by 13.48% to $60.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $60.8 million, $70.2 million, and $79.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | 125.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.76 Mn |
| Dec 31, 2025 | 70.22 Mn |
| Sep 30, 2025 | 79.65 Mn |
| Jun 30, 2025 | 87.32 Mn |
| Mar 31, 2025 | 86.37 Mn |
| Dec 31, 2024 | 84.37 Mn |
| Sep 30, 2024 | 93.85 Mn |
| Jun 30, 2024 | 108.27 Mn |
| Mar 31, 2024 | 122.84 Mn |
| Dec 31, 2023 | 135.15 Mn |
| Sep 30, 2023 | 142.87 Mn |
| Jun 30, 2023 | 118.71 Mn |
| Mar 31, 2023 | 98.56 Mn |
| Dec 31, 2022 | 108.26 Mn |
| Sep 30, 2022 | 117.18 Mn |
| Jun 30, 2022 | 125.74 Mn |
| Mar 31, 2022 | 136.16 Mn |
| Dec 31, 2021 | 147.86 Mn |
| Sep 30, 2021 | 157.59 Mn |
| Jun 30, 2021 | 170.11 Mn |